Roger Adsett Sells 88,060 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. The trade was a 45.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, February 3rd, Roger Adsett sold 791 shares of Insmed stock. The shares were sold at an average price of $156.17, for a total value of $123,530.47.
• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $140,406.14.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57.

Insmed Stock Performance

Shares of NASDAQ:INSM remained flat at $162.43 during midday trading on Friday. The stock had a trading volume of 1,809,313 shares, compared to its average volume of 2,579,325. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The stock’s 50 day moving average price is $150.18 and its 200 day moving average price is $166.38. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $35.01 billion, a P/E ratio of -25.34 and a beta of 1.10.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.32) EPS. Sell-side analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently modified their holdings of INSM. CIBC Private Wealth Group LLC boosted its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. Kingsview Wealth Management LLC lifted its position in shares of Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 60 shares in the last quarter. Choreo LLC lifted its position in shares of Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Insmed by 10.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 69 shares during the period. Finally, ORG Partners LLC grew its position in shares of Insmed by 12.7% during the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a research note on Friday, January 23rd. Leerink Partners raised their target price on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. Guggenheim lowered their target price on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Jefferies Financial Group started coverage on Insmed in a report on Monday, March 16th. They set a “buy” rating and a $228.00 price target for the company. Finally, Mizuho upped their price target on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Insmed has an average rating of “Buy” and a consensus price target of $212.67.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.